Our Mission
Develop and conduct Investigator-Initiated clinical trials and research about thrombosis in the United States (U.S.).
VENUS is the only clinical trial network in the U.S. focused solely on venous thrombosis and counts more than 128 investigators in 38+ states. As a member of the International Network of VENous Thromboembolism (INVENT), VENUS fosters international collaborative research.
- 5-8% of the U.S. population has a genetic risk factor for VTE
- 900,000 Americans are diagnosed with a form of VTE each year
60,000 - 100,000
Americans die of DVT/PE each year
1/3 - 1/2 people
with DVT will experience long-term complications
Half of blood clots
occur during or soon after a hospital stay or surgery
1/3 of people
with DVT/PE will have a recurrence within 10 years
Source: Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2363-71. doi: 10.1161/ATVBAHA.114.304488. PMID: 25304324.